Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 28articles · 30d
- 6+ hour agolatest article
- Aug 17, 2026earliest in window
- 96%with images
- 342avg words
- Medical 21
- Health & Wellness 18
- Economy, Business & Finance 11
- Health 11
- Business & Industrial 6
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
8+ hour, 8+ min ago (260+ words) Six patients who had lived with binge eating disorder for as long as two decades sat down for two infusions of an experimental psychedelic drug. Three months later, all of them were still doing better. Half of them had not…...
Noxopharm moves lupus skin therapy toward next human trial
6+ hour, 28+ min ago (292+ words) Noxopharm has announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful and disfiguring skin condition for which no targeted treatment currently exists. The Sydney-based company said the…...
US health agency funds broad access trial for Melbourne biotech's ALS drug
5+ day, 4+ hour ago (444+ words) The United States National Institutes of Health has agreed to fund a multimillion-dollar program that will give up to 200 Americans living with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology company Neurizon Therapeutics. The grant,…...
Radiopharm imaging trial offers new hope for pancreatic cancer detection
5+ day, 4+ hour ago (245+ words) Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest to treat forms of cancer. The Sydney-based, dual-listed biopharmaceutical company, which…...
OncoSil marks a milestone moment for pancreatic cancer patients in Spain
5+ day, 6+ hour ago (239+ words) A hospital in Madrid has reached a notable milestone for OncoSil Medical, with the Australian medical device company confirming that its device has now been used to treat its 100th patient in Spain. The procedure took place at Hospital HM Sanchinarro....
Emyria prepares to open its first Sydney mental health clinic
6+ day, 12+ hour ago (219+ words) Emyria is on the verge of opening its first clinic in Sydney, marking the company's entry into New South Wales and extending its national network of intensive mental health services into Australia's most populous state. The ASX-listed company told investors…...
Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients
1+ week, 9+ hour ago (412+ words) BiotechDispatch Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of…...
Australian biotech Immuron takes gut health treatment to the US market
1+ week, 9+ hour ago (359+ words) BiotechDispatch Australian biotech Immuron takes gut health treatment to the US market Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science company Calmino Group AB....
Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage
1+ week, 9+ hour ago (504+ words) BiotechDispatch Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage Neurizon Therapeutics, the Melbourne-based biotechnology company developing a treatment for the fatal neurological disease ALS, has appointed Dr Chris Bremer as its new…...
Prescient reaches key PTX-100 trial checkpoint ahead of December review
1+ week, 4+ day ago (338+ words) Prescient Therapeutics has reached an enrolment milestone in its Phase 2a trial of PTX-100 for patients with relapsed or refractory cutaneous T-cell lymphoma, setting the company up for a planned dose optimisation review in December. The Melbourne-based clinical-stage oncology company said…...